Focusing on drugs that appeared to reverse cancer-related gene expression signatures, researchers identified candidate compounds that thwarted cancer cell lines.
In PNAS this week: high-altitude adaptation signature among Tibetans, de novo mutations in early-onset high myopia, and more.
The MIT researchers said that the mutational signature could be used to identify people exposed to aflatoxin who are at risk of developing liver cancer.
The University of California, Los Angeles-led team said the approach outperformed two established classification methods.
Researchers combined a microfluidic technology called the CTC-iChip with digital PCR to potentially improve cancer detection in hepatocellular carcinoma patients.
In PNAS this week: mutation patterns in uterine and ovarian carcinosarcomas, deep genome sequences, and more.
TwoXar will work with Stanford's Asian Liver Center to identify and validate computationally-derived drug candidates that target hepatocellular carcinomas.
In Nucleic Acids Research this week: CHOPCHOP web tool update, human retina transcriptional atlas, and more.
A team of researchers has characterized the mutations commonly found in liver cancer, and suggests that the disease may be genomically heterogeneous.
In PNAS this week: common variants that influence viral load in HIV patients, tumor evolution patterns, and more.
A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.
Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.
Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.
In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.